Abstract | The promise of targeting epigenetic abnormalities for cancer therapy has not been realized for solid tumours, although increasing evidence is demonstrating its worth in haematological malignancies. In fact, true clinical efficacy in haematopoietic-related neoplasms has only become evident at low doses of epigenetic-targeting drugs (namely, inhibitors of histone deacetylase and DNA methyltransferases). Describing data from preclinical studies and early clinical trial results, we hypothesize that in using low-dose epigeneticmodulating agents, tumour cells can be reprogrammed, which overrides any immediate cytotoxic and off-target effect observed at high dose. We suggest that such optimization of drug dosing and scheduling of currently available agents could give these agents a prominent place in cancer management-when used alone or in combination with other therapies. If so, optimal use of these known agents might also pave the way for the introduction of other agents that target the epigenome.
Introduction
One of the most of exciting areas of biology over the past decade has been the expanding understanding of how epigenetic control influences the patterns of gene expres sion in cells. [1] [2] [3] This knowledge has immediate transla tional implications for targeting epigenetic abnormalities in cancer for therapeutic purposes.
In principle, 'epigenetics' refers to the somatically he ritable differences in gene expression not attributable to intrinsic alterations in the primary sequence of DNA. 4 In this paradigm, the DNA serves as a 'hard drive' of genetic information that requires the 'software' package of epigenetic control to determine its full transcriptional output. 1, 2 In a single individual, cells of different types all have the same genome, but have multiple complex and different 'epigenomes' that define their respective phenotypes. [1] [2] [3] Epigenetic control occurs throughout the genome-as well as in regulatory elements distant from the genes they control-and can mediate interactions between chromosomes. 3 Core elements of the epigenetic regulation of gene expression include how DNA is pack aged or wrapped around nucleosomes, and how those nucleosomes are positioned throughout the genome (Figure 1) . [5] [6] [7] Key regulatory features include how chrom atin and nucleosomes are modified by a complex series of enzymes and their subsequent interaction with pro teins that recognize these modifications. [5] [6] [7] [8] Cancers of all types, and even different cell populations within a single patient's cancer, have different genomes result ing from the many mutations that alter the DNA hard drive. In addition, extensive and biologically si gnificant changes in the epigenetic software package are increas ingly recognized; these changes constitute the 'cancer epi genome' . 1, 2 Rapid advances in technology are enabl ing the ever morerobust interrogation of this complex control of gene expression and the findings are informing drugdevelopment strategies. 3 Accordingly, the cancer cell can be summed up to represent a complex interplay between genetic and epi genetic abnormalities that, from beginning to end, drive the evolution of each patient's malignancy. One exciting development is the recognition that virtually all tumours harbour mutations in genes that encode proteins that control the epigenome. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] As we start to understand the precise relationships between these mutations and the consequences for cancer cell phenotypes, these observa tions will increasingly guide therapeutic strategies for epigeneticmodulating agents. The current theory is that the mutated genes 'set up' downstream abnormalities in the epigenome. [21] [22] [23] The downstream genes affected by these epigenetic abnormalities are generally wildtype for the underlying DNA sequence. Thus, normal func tion might be restored since, theoretically, reverting the software package of epigenetic abnormalities should be easier than repairing the hard drive that harbours the upstream mutations.
In the past when genomewide data were lacking, the epigenetic research community focused heavily on regulatory mechanisms biased to gene start sites. 20 This focus arose from the initial discoveries that cancer specific hypermethylation changes were often found in CpG islands (socalled as they are rich in cytosine and guanine) in gene promoters. Studies are now expand ing our view of the genomewide role of epigenetics.
The concept of epigenetic therapy has also focused largely on changes at gene promoters, which will surely shift to (and be integrated with) studies of cancer e pigenetic ab normalities across the genome.
Indeed, the rapidly growing field of therapeutic e pigenetics is being enhanced by the merging of lab oratory and clinical data that are instructing us on how epigenetic modulators best provide meaningful benefit to patients. To date, the bestcharacterized and only FDA approved epigenetic modulating antineoplastic agents have targeted abnormalities in DNA methylation and histone acetylation (via histone deacetylase; HDAC) in haematological malignancies. [24] [25] [26] [27] [28] [29] [30] [31] [32] Emerging data is now instructing the epigenetics research community on how to better use epigenetic drugs, including lowering doses and the rational sequence of treatment approaches with other agents. 67 Importantly, these lessons are informing the clinical assessment of epigenetic drugs in patients with solid tumours, with compelling results, which we discuss in this Review. We focus on the growing body of data centred on promoters, which illustrates that targeting epigenetic abnormalities is an exciting concept with the potential to improve the management of patients with cancer. We believe the principles of epigenetic therapy will help guide novel therapeutic concepts, and the rapidly strengthening focus on the entire cancer epigenome will enrich these therapeutic possibilities even further.
Principles of epigenetic therapy
The epigenetic targets Currently, the most studied and recognized cancerspecifi c epigenetic changes are alterations in DNA methylation and histone acetylation, which have been extensively reviewed previously. 2, 20, 33, 34 Briefly, these modifications include global hypomethylation, regional hypermethyla tion and chromatin events that are closely tied to DNA methylation changes.
Hypomethylation of tumour genomes is often observed within the body of genes and in regions flank ing genes. 1, 20, 34 Meanwhile, cancerspecific regional hypermethylation (of hundreds of genes per tumour) typically involves normally unmethylated, CpGenriched DNA-the CpG islands residing in and around proximal gene promoters. 2, 20 This hypermethylation can be associ ated with decreased gene expression. Indeed, some data indicate that 'shore' regions (adjacent to CpG islands) distant to transcriptional start sites can also have an important role in gene expression through their hyper methylation. 35 The increased methylation patterns in promoters provide an alternative mechanism to muta tions by which lossoffunction mutations of key tumour suppressor genes can occur, and are now recognized as an early and central event in carcinogenesis. 2, 20, 33 Finally, cancerspecific epigenetic chromatin events also typi cally involve modifications of histone proteins, includ ing universal decreases in histone acetylation as well as decreases in an active mark of gene transcription (methyl ation at lysine 4 of histone 3; H3K4) at promot ers of DNA hypermethylated genes. These changes result in a closed chromatin configuration and decreased gene expression ( Figure 1 ). Increased H3K4 methylation creates resistance to DNA methylation. 124, 125 Reversing low histone acetylation is one possible method for epigenetic cancer therapy, by targeted inhi bition of histone deacetylase. [36] [37] [38] However, it is impor tant to consider that, in the interplay between DNA methyl ation and chromatin abnormalities in cancer, either aberration can be the dominant driver for tumori genesis. Thus, chromatin modifications can, even in the absence of DNA methylation, be determinants of altered patterns of gene expression. 5, 20 For example, increased p olycomb silencing protein complexes (PcG), which result in increases in the repressive chromatin mark of H3K27 methylation, seem to render many genes vulnerable to abnormal promoter DNA methylation during tumorigenesis. 20, [39] [40] [41] This cascade results in the silencing of genes involved in important protections against neoplasia, including tumour suppressors, regu lators of immune escape and apotosis. These chromatin changes, as well as abnormal DNA methylation, com prise a growing focus of strategies to reverse epigenetic ab normalities to provide novel cancer treatments. [42] [43] [44] Optimizing epigenetic therapy Against the backdrop of these complexities for epigenetic control of gene expression in cancer, epigenetic therapy can be a unique type of targeted therapy. In effect, the aim is to reverse the abnormal cancer epigenome in a scen ario not unlike the cellular reprogramming used when, for example, inducing an embryonic phenotype from a mature cell to prepare induced pluripotent stem cells (iPSCs). 45, 46 For iPSCs, every aspect of the epi genome of the mature cell must be driven 'backwards' to create the stem cells and this requires changing the DNA meth ylation and chromatin patterns. Interestingly, the DNA demethylating agents and inhibitors of HDACs used as therapeutic agents can act as small molecules to improve the efficiency of preparing iPSCs. 47 This fact emphasizes the mechanisms underpinning these drugs in the man agement of patients with cancer. We hypothesize that, by targeting virtually any component of the abnormal epigenetic processes in cancer, we will almost always affect the multiple altered signalling networks 48, 49 that drive tumorigenesis to therapeutic advantage ( Figure 2) .
Thus, reversing DNA methylation or chromatin ab normalities in cancer will seldom target one spe cific gene, which could be construed as a nonspecific mechan ism of action of epigenetic drugs. However, in reality this 'lack' of specificity might lie at the heart of its value. The challenges are to understand and maximize (for clinical advantage) the biological facets of epigenetic therapy. A key starting point to consider is, although cancerspecific DNA hypermethylation can affect several known tumour suppressor genes-such as CDKN2A (p16), MLH1, APC and other canonical WNT pathway genes 2,20 -many more genes are simultaneously hyper methylated in each patient's cancer. 1, 2, 20 Indeed, for every genetic mutation in a given patient's tumour, hundreds of genes have epigenetic abnormalities within the deviant cell signalling pathways that drive tumorigenesis. 32, 33 Among the genes scattered throughout the pathways, many important candidate genes or groups of genes exist, the loss of function or expression of which can be critical to the initiation and progression of tumours as well as to their sensitivity and resistance to chemotherapy ( Figure 3 ). Consequently, alterations to these genes can 'lock in' abnormal cell selfrenewal or diminish the dif ferentiation capacity of cancer cells. 50, 51 For traditional targeted therapies aimed at a single gene mutation, such as EGFR mutations in lung cancer, 52 ,53 the existence of multiple signalling abnormalities poses a great chal lenge for the durability of the therapeutic responses. Compensatory intrasignalling and intersignalling pathway events can lead to resistance to the inhibition of any single genemediated event to which a cancer cell is addicted. [54] [55] [56] [57] [58] The broad advantage of epigenetic therapy lies in reversing these changes simultaneously via multiple signalling pathways, which can durably damp down many of the compensatory events that ultimately defeat other targeted approaches ( Figure 2 ). That is, epigenetic agents can function predominantly as media tors of a cell reprogramming effect to inhibit cancer ini tiation and progression. Furthermore, epigenetic agents are useful when used either alone or in combination to sensitize tumour cells to cytotoxic agents or to slow or reverse resistance to other targeted approaches. We believe these concepts are crucial for how one designs and tests-preclinically and clinically-agents touted as epigenetic therapy.
DNA demethylating agents
The efficacy of decitabine and 5azacitidine (both i nhibitors of DNA methyltransferase) in the manage ment of myelodysplasia and acute myelogenous leukae mia (AML) is well known. These drugs were initially designed and tested as cytotoxic chemotherapy in the 1960s 59, 60 and some 20 years later were discovered to have DNA demethy lation activity. 61 Their developmen t and subsequent FDA approval-decitabine was approved in 2006 for myelodysplasia and AML, whereas 5azacitidine was approved in 2004 for myelodysplasia-was achieved by markedly reducing the doses to overcome limiting t oxicities, which also likely enhanced their targeted effects on DNA methyltransferases (Table 1) . Indeed, the development of decitabine and 5azacitidine was severely h ampered for decades because, as for the vast majority of all anticancer drugs, initial trials used standard designs to escalate drug doses until maximally tolerated doses were reached. These doses proved to be substantially toxic to patients (likely because of offtarget epigenetic modula tion) and dose deescalation was needed to achieve both improved tolerability and activity. 32 The lessons learned from this evolution should strongly inform laboratory research and clinical trials that examine DNA demethyl ating agents for the management of advanced lung cancer 62 and possibly other solid tumours. As gleaned from the studies of lessons of decitabine and 5azacitidin e, 126 low doses of the drugs minimized toxicity while potentially retaining the inhibition of DNA methyltransferases by incorpor ating into DNA and then covalently binding all three biologically active forms of these enzymes. By this mechanism, the agent irre versibly inhibits DNA methyl transferase catalytic sites for methyl ation and triggers their degradation. 42, [63] [64] [65] [66] With higher doses of the drugs, offtarget effects can be exerted, such as triggering DNA damage to evoke cell cycle check points, which is immediately cytotoxic. 42 When used at low doses in patients with myelodyspla sia, pharmacokinetic studies indicated that tumour cells are exposed to nanomolar concentrations of the drug at which cytotoxic effects are not the prevailing mode of action. Indeed, our laboratory studies data these con cepts. 67 We showed that one 3day treatment of cancer cells of multiple histologies using lowdose 5azacitidin e resulted in minimal cell death, but gene expression (lasting weeks) increased cell signalling, including increased expression of immune response and pro apoptotic genes. Moreover, this single ex vivo treatment followed by implantation of cells in immuno suppressed mice resulted in slowed tumour engraftment and sub sequent tumour growth through multiple passages over several months. Low nanomolar doses seem to minimize offtarget effects and enable cancer cellsto undergo cel lular reprogramming associated with a loss of longterm clonogenic or tumorigenic capacity. 67 These effects are accompanied by partial genomewide DNA demeth ylation and altered gene expression events that poten tially reverse signalling events in the multiple pa thways (Figure 2 ) thought to drive tumorigenesis. 67 Importantly, these antitumour effects have been observed in cultured and primary cancer cells that constitute tumour stemlike cells with increased self renewal capacity. 67 This result suggests that certain epigenetic therapies could achieve the highly desired goal of blunting these cells, which are resistant to most standard therapies. 68 The results can also help explain why many patients with myelodysplasia and AML take several months to respond to lowdose 5azacitidine-progressiv e exhaustion of resistant stemlike cells could require an extended period of time for the effects to be evident. As a case in point, Silverman et al. 69 reported that a considerable number of patients (48%) with high risk myelodysplasia who continued on DNA demethyl ating drugs past their first response had increased magnitudes of response with further treatment. Our multiinstitutional, multidisciplinary StandUp to Cancer (SU2C) group has worked to accelerate the laboratory and clinical research of epigenetic therapy for cancer treatment in the most common human cancers. For example, on the basis of these translational and clinical data, we have taken a lowdose 5azacytidine strategy, combined with the HDAC inhibitor entinostat, to phase II trials for common solid tumours (non smallcell lung cancer [NSCLC], colorectal and breast cancers). Encouragingly, the regimen, which is well tolerate d and clinically active in patients with myelodys plasia and AML, 70 seems to have compelling activity in patients with solid tumours. 62 Specifically, results in patients with advanced, heavily pretreated NSCLC are promising and suggest that epigenetic therapy could rep resent a major change in the management of this deadly cancer. 62 Although the epigenetic therapy alone achieved responses in only 3% of patients who were heavily pre treated (median of three prior therapies), the responses were remarkably durable and resulted in survival from just under 3 years to over 4 years. 62 For comparison, in the phase III study showing efficacy of pemetrexed as a secondline therapy in advanced NSCLC (in patients who had only one prior therapy), no patients survived past 22 months.
These encouraging results could be improved upon if patients are appropriately preselected. Such Figure 3 | Concurrent widespread changes in gene expression with epigenetic therapy. Anticancer efficacy of treatment with epigenetic-modulating agents is ssociated with widespread changes in gene expression that affect multiple biological processes. Gene expression is increased through direct reversal of epigenetic modifications of genomic DNA, whereas, for cancer-promoting genes, gene expression is reduced by the re-expression of their regulatory genes. Abbreviation: EMT, epithelial-mesenchymal transition. personalization will require analyses of pretreatment and posttreatment tissue samples, which were not available from our first trials, to evaluate possible methylation specific (and other) biomarkers that could identify patients most likely to benefit from the therapy. Such biopsy studies are essential for all trials moving forward; the approaches for identifying useful biomarkers are constantly being enriched by a large body of research in cancer epigenetics. For example, our small pilot study of candidate genes in NSCLC revealed that the demethyl ation of a set of four epigenetically silenced genes (p16, CDH13, RASSF1A and APC) could be detected in sequential blood samples of patients and tracked with improved progressionfree survival and overall sur vival. 55 These four genes had previously been reported to be predictors of early recurrence in early stage lung cancer. 71 Indeed, many such candidate genes can be identified for lung and other solid tumours from the extensive studies in the field. 20, [72] [73] [74] Moreover, genome wide surveys of DNA methylation changes in multiple tumour types, such as those in the Cancer Genome Atlas Project (TCGA), [72] [73] [74] will provide a great number of gene promoter and other genomic sites of DNA methylation abnormalities to consider. For example, the DNA pro moter sites encoding microRNAs (miRNAs) can become abnormally methylated, which is associated with loss of expression of the miRNA. 75 These changes could be critica l with respect to pathway changes that are affected.
The basal methylation status of genes, responses of these loci to the initial cycles of low doses of DNA demethylating drugs, the accompanying gene expres sion changes and the pathways altered will all be pivotal to guide personalization of any epigenetic treatment paradigm. Such individualization must also consider the integration of DNA methylation patterns with the genetic abnormality of each tumour type approached. This need has been elevated by the previously mentioned frequency of mutations in genes encoding for protein regulators of the epigenome. 20, 76 DNA methylation pat terns specifically accompanying these genetic changes are already being recognized, 77 and the genes involved might be important for tailoring biomarker approaches to specific tumour types and their subgroups. Finally, DNA polymorphisms-some of which are inheritedcan affect gene regulatory regions and are beginning to be linked to abnormal gene promoter DNA methylation events in cancer. [78] [79] [80] These polymorphisms probably function by providing a decreased basal transcriptional activity of the gene, making it vulnerable to the evolution of abnormal DNA methylation during the initiation and progression of tumours. 78, 80, 81 Nearly 20% of the heavily pretreated patients with advanced NSCLC enrolled in our initial epigenetic therapy trial lived for ≥1 year (and up to >4 years) after the initial therapy. 62 Expected survival at 6 months for patients after three lines of therapy, such as ours, is 48% based on a large, retrospective observational study. 82 This survival might be attributable to prolonged response or disease stabilization from the epigenetic therapy. However, we observed an unusually robust response to subsequent cytotoxic therapies, with which the majorit y of patients were treated. 62 Approximately 25% of the patients, which is considerable in the NSCLC setting, achieved Response Evaluation Criteria in Solid Tumors (RECIST) responses to therapies following even short courses (~two cycles) of the epigenetic treatment. 62 These responses clinically reinforce the laboratory findings that longlasting cellular reprogramming occurs as a result of epigenetic targeting. If these clinical benefits are validated in the already planned larger clinical trials (which is cur rently under consideration by the institutional review board at Johns Hopkins University), the m anagement of NSCLC could be substantiall y improved.
Other researchers are achieving results in the l aboratory and in clinical trials that are consistent with these initial findings. For example, Humenuik et al. 83 showed that colorectal cancer cell lines exposed to increasing 5fluorourac il concentrations generate acquired resistance to downregulated UMPCMP kinase, which is an impor tant effector of 5fluorouracil activity. With lowdose decitabine treatment, UMPCMP kinase levels increased and the resistance to 5fluorouracil was reversed. 83 In another study, combination decitabine and trichostatin A (an HDAC inhibitor) resulted in decreased expression of the multidrug resistance transporter ATPbinding cassette subfamily G member 2 (encoded by ABCG2) as well as markers of enhanced selfrenewal populations in ovarian cancer cells, and increased the sensitivity of these cells to cisplatin in vivo. 84 In relapsed childhood acute lympho blastic leukaemia (ALL) and Blymphoblastic leukeamia, blasts isolated from patients displayed a methylation signature indicating that acquired resistance to standard chemotherapy is associated with epigenetic changes; pre treatment with vorinostat (an HDAC inhibitor) and decit abine restored chemosensitivity in these cells. 85 A study based on these findings of decitabine and vorinostat in combination with chemotherapy in relapsed child hood ALL is ongoing and preliminary activity has been reported (P. Brown, personal communication). Other studies have suggested that lowdose decitabine is effica cious in terms of antitumour effects, as well as promoting immune recognition through increasing expression of cancer testis antigen, in a model of pancreatic cancer. 86 Such results have been translated to the clinic to mean ingful effect, notably in ovarian cancer-multiple groups have reported the use of demethylating agents to restore platinum sensitivity in patients with platinumresistant ovarian cancer. Fu et al. 87 reported a phase I/II study of 5azacitidine and carboplatin that demonstrated durable responses and stable disease (median duration of therapy 7.5 months) in 46% of patients with platinumresistant or refractory ovarian cancer. A similar study of decitabine and carboplatin in the same patient population reported a 40% 6month progressionfree survival rate, with one patient having a complete response. 88 Larger trials testing demethylating agents to overcome platinum resistance are currently ongoing.
The mechanisms leading to sensitization for s ubsequent cytotoxic therapies must be established in the laboratory. However, many of the pathways found to be altered in our recent lowdose studies, such as decreased activity of cellcycle pathways and enhanced apoptosis, are predicted to provide such sensitization. 67 In fact, many of the proteins altered-such as FOXM1, polo kinase 1 and Aurora kinase A and B-are being targeted by the pharmaceutical industry for such pur poses. 67 These studies support the hypothesis that epi genetic therapy functions by reprogramming cancer cells to a more chemosensitive, less stemcelllike phenotype through the reexpression of various groups of genes in multiple anticancer pathways.
Histone deacetylase inhibitors
HDAC inhibitors are the other major class of e pigenetic modulating agents that have been tested and approved for the treatment of cancer. As single agents, approved use is limited to lymphoma-both romidepsin and vorino stat have FDA approval in c utaneous Tcell lymphoma, whereas romidepsin is also approved for use in patients with relapsed peripheral Tcell lymphoma. [28] [29] [30] [31] Multiple HDAC inhibitors are in preclinical and clinical trials, the details of which have been discussed elsewhere. 36 Targeting HDACs is more complex than targeting DNA methytransferases because this group of proteins has multiple subclasses with mechanisms of action still under contention. 89 In fact, proteins other than histones are targets of the lysine deacetylation effects of these drugs. For example, even inhibitors that preferentially target nuclear class I HDACs can alter the transcrip tional activity of the tumour suppressor p53 by altering its acetyl ation status. 90 Furthermore, not all HDACs are located in the nucleus, 89 which means they probably do not target histone acetylation. For example, class III HDACs are a separate group of NADdependent enzymes, among which NADdependent protein d eacetylase sirtuin1 (hSIRT1) is best studied. hSIRT1 regulates key histone marks, with important transcrip tional control consequences that include H4K16 acetyl ation. 91, 92 This enzyme has increasingly been implicated in the altered gene expression in cancer, and its inhibi tion might have clinical relevance. 93 hSIRT1 inhibition is associated with p53independent apoptosis in cancer cells after DNA damage, and its inhibition could have therapeutic efficacy when used alone or in combina tion with other drugs. Uncertainty persists regarding which of the many potential targets of HDAC inhibitors are responsible for their anticancer effects. 94 However, multiple studies have demonstrated that HDAC inhibi tion results in reproducible increases in gene expression of important tumour suppressor genes (including p53, SFRP1, miR375 and DAPK) [95] [96] [97] and can slow tumour growth and sensitize cells to other therapies, including cytotoxic agents and signal transduction inhibitors.
Against this background, multiple mechanisms of action of HDAC inhibitors have been observed in preclinical studies, both epigenetic and cytotoxic. 37, 38, [98] [99] [100] Similar to results of DNA demethylating agents, these effects are probably dosedependent. 37, 38, [98] [99] [100] For example, HDAC inhibitors being used at high doses in the clinic seem to cause rapid extension of DNA damage and impaired repair of induced DNA breaks. 100, 101 The consequences for these effects are rapid cellcycle arrest and cell death typical of cytotoxic agents. 37, [98] [99] [100] Presumably, such rapid effects are not the ultimate goal and do not represent the optimal use of these drugs (com parable to DNA demethylating agents). In fact, effects of these high doses might well explain why they have not achieved high efficacy for the treatment of most common human cancers. That is, these immediate effects preclude the cellular reprogramming that alters the disease biology in a durable, clinically meaningful fashion.
Given these limitations, HDAC inhibitors could still be extremely powerful tools-if used with the right timing, doses and combinations-to provide a robust component of epigenetic therapy with widespread efficacy. As noted earlier, one key advantage of epigenetic therapy is the ability to inhibit subpopulations of cancer cells that drive tumorigenesis and are usually resistant to most therapies. Although the precise definition of these stemlike cells is still controversial, the heterogeneity of cancer cells on a molecular level is wellaccepted. [102] [103] [104] [105] Most impor tantly, extensive plasticity among cell populations in both normal cells and in tumours is needed to generate these cells, otherwise cells would be unable to change their phenotype. [102] [103] [104] [105] Although the resistance of these stemlike cells to therapies might, in some instances, be fixed by mutations, solid experimental evidence dem onstrates that epigenetic factors might regulate both the plasticity of their formation and the mediation of treat ment resistance. 68 A widely noted example of this balance stems from a series of experiments by Settleman and col leagues, 68 which suggests that resistance to treatment of multiple cancer cell types, against both targeted therapy agents and traditional chemotherapy drugs, centres on the creation or persistence of drugtolerant, stemlike cells that are driven by epigenetic control. One protein that was highly upregulated in stemcelllike, therapy resistant populations was lysinespecific demethylase 5A (encoded by KDM5A), a histone demethylase that con trols the H3K4 mark for active transcription. 68 Settleman et al. 68 also showed that low doses of clinically relevant HDAC inhibitors, including entinostat, could reversibly, and without initial cytotoxicity, eliminate drugresistant cells persisting in cultures treated with highly active targeted inhibitors. Furthermore, a related enzyme, lysinespecific demethylase 5B, has been shown to be a key driver for stemlike cells in cultured and primary human melanoma. 106 These findings have tremendous relevance for potential strategies to maximally employ HDAC inhibitors in the management of human cancers.
Given this background, whether HDAC inhibitors will provide clinical benefit to patients remains to be seen. As previously mentioned, the HDAC inhibitors romidep sin and vorinostat have both been approved by the FDA for haematological malignancies owing to their ability to produce remarkable, if not considerably durable, responses in approximately 30-40% of patients with Tcell cutane ous lymphomas. [28] [29] [30] [31] However, the mechanisms under lying the robust initial sensitivity of these tumours have yet to be defined. Obviously, gaining such insight would markedly enrich strategies for using HDAC inhibitors in the clinic. The paucity of definitive cell culture lines for Tcell cutaneous lymphomas seems to limit progress in this arena.
Outside of these successes, HDAC inhibitors used alone have had little success, as yet, in clinical trials for a variety of solid tumour types, including thymic cancer, glioblastoma, renal cell carcinoma, hepatocellular carcin oma, [107] [108] [109] [110] [111] ovarian cancer and others. 37, 38, 98 However, the work of Settleman et al. 68 suggests that HDAC inhibi tors could reverse treatment resistance or sensitize tumours to treatment, which might have some bearing on the growing body of clinical data consistent with this hypothesis. Very prominent among these are studies in patients with NSCLC and breast cancer that suggest com bining HDAC inhibitors with established therapies might work. In a randomized phase II trial, the HDAC inhibitor entinostat combined with the EGFR inhibitor erlotinib showed no overall benefit relative to erlotinib alone in patients with recurrent advanced NSCLC. However, in a subset of patients with high baseline Ecadherin levels, a significant overall survival benefit was evident (9.4 months versus 5.4 months, P = 0.03). 112 In a second study, vorinostat therapy increased response rates sig nificantly from 12.5% to 34% when combined with carboplatin and paclitaxel in treatmentnaive patients with metastatic NSCLC, with a trend towards improved progressionfree survival and overall survival as well. 113 Finally, in a phase II trial in patients with breast cancer, entinostat significantly increased survival when com bined with an aromatase inhibitor. 114 At median follow up of 25 months, treatment with exemestane with entino stat versus exemestane alone resulted in an 8.3month improvement in overall survival (P = 0.04). This latter study is perhaps the most promising of those in solid tumours and warrants additional testing for validation. However, for these studies, the true mechanisms for the results are-crucially-far from clarified and the doses of HDAC inhibitors used highlight specific ontarget effects rather than offtarget cytotoxic effects.
Future outlooks
We believe that the best hope for future clinical trials with DNA demethylating agents and HDAC inhibitors lies in critically analysing what emerging laboratory and clini cal studies have to teach us. Firstly, the data support that these drugs will not work best when doses that produce immediate cytotoxic effects are used; such cytotoxic doses prevent the reprogramming of cancer cells and preclude durable clinical consequences. As with all anti cancer therapies, even with lower doses, a therapeutic window must be established in which normal tissue is relatively preserved and tumour tissue is affected. The major challenge for all these epigenetic therapies is deter mining what that window is, which will require close scrutiny of both acute and chronic toxic effects. Assessing methylation and expression differences in normal versus tumour tissues using in vivo laboratory studies and sequential biopsy analyses, where feasible, in patients participating in welldesigned translational studies, should enable the necessary quantitative assessments.
Secondly, these agents are best used in the clinic when adequate time for response is possible because the epi genetic reprogramming takes longer to become appar ent than the actions of traditional chemo therapies. Accordingly, the RECIST criteria commonly used to assess clinical responses within 6-8 weeks will often be suboptimal for monitoring clinical trials of epi genetic therapy-patients might need to be continued on therapy if they are clinically stable. This paradigm has been used in the immunology arena whereby responses are expected to take time to develop, and interim disease progression followed by response has been observed. 115 Furthermore, trials need not depend solely on shortterm criteria for monitoring results. Longterm clinical benefits must be rigorously assessed using careful followup measurements of response to subsequent therapies and, of course, overall survival should be maintained as the key end point incor porated into clinical trial designs, as we emphasized in our lung cancer trial. 62 Immediate response criteria would have precluded the documentation of the benefits of DNA demethylating agents for patients with myelodysplasia and AML, which only emerged after months of treat ment and, in some cases, a worsening of disease before any benefit became apparent.
These caveats also apply to trials of other targeted agents; an excellent example is of antitolerancedisruptin g immunotherapy approaches, which required prolonged time courses. 115, 116 Accordingly, in monitoring epi genetic therapy in patients, acknowledging the likelihood that traditional initial tumour responses will not often be evident is important. Rather, the end points of clini cal trials should permit the evaluation of the biological changes to the behaviour of the tumour-end points such as changes in the pace of the disease or response to su bsequent therapy as well as overall survival.
With these criteria in mind, we believe current DNA demethylating agents and HDAC inhibitors have a promising future in the treatment of the most common solid tumours. Careful biomarker work within the trials and, preclinical work conducted in parallel, is manda tory to fully evaluate the mechanisms underpinning any observed clinical efficacy. Genomewide studies of DNA methylation, lysine acetylation studies, geneexpression studies and the assessment of protein targets all must be combined with candidate gene approaches to define all possible predictive biomarkers. Direct examination of tumour cells or tissues should be complemented with serum sample analyses to identify and monitor patients who are most likely to benefit from these agents.
Perhaps the greatest impact of epigenetic therapy for cancer management will involve combination with current chemotherapeutic approaches. Reversing resist ance or sensitizing cancers to multiple therapy types, including hormonal therapies, immunomodulatory th erapies and standard chemotherapy, are now very promising and rational concepts. However, particular care must be taken with dosing and scheduling if these agents are to be combined with standard agents, for reasons of efficacy and tolerability. For example, dosing must be chosen to minimize toxicity for the epigenetic therapy leadin and to maintain optimal dosage of the standard agent. Wisely designed clinical trials should be increasingly instituted to realize this promise.
We must also consider the development of new agents for targeting the cancer epigenome. Such agents will include new derivatives of current drugs as well as novel drug design concepts. One example is the design of a prodecitabine drug, SGI110, which is in phase I/II trials and shows promise in patients with in myelodysplasia and AML. 117 Additionally, an oral form of 5azacitidine, which has obvious compliance and convenience advantages, is now also in clinical trial. 118 Finally, assessing other thera peutic targets, such as histone methyltransferases and the BET family of proteins, is an emerging theme. 37, 38, [119] [120] [121] [122] The bromodomain inhibitors of the BET family, which are hypothesized to block activation of MYC target genes mediated by BET proteins, are now entering clinical trials. As with DNA methyltransferase and HDAC inhibitors, these new targets invite exploration for use in combi nation regimens and must be explored preclinicall y to determine any underlying mechanistic features that can improve efficacy.
Conclusions
The rapidly growing field of therapeutic epigenetics is being enhanced by robust translational approaches that have married laboratory and clinical data to suggest how epigenetic drugs best provide meaningful benefit to patients. These data suggest that epigenetic agents can have considerable clinical effect through repro gramming malignant cells, which could fundamentally change the management of patients with cancer. With thoughtful preclinical and clinical study design, we are poised to fully elevate epigenetic therapy to a prime position in cancer therapy.
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